These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 23640528

  • 1. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [Abstract] [Full Text] [Related]

  • 2. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract] [Full Text] [Related]

  • 3. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
    Moorman ML, Nash JE, Stabi KL.
    J Trauma Acute Care Surg; 2014 Sep 15; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
    [No Abstract] [Full Text] [Related]

  • 4. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM, Garcia DA, Crowther MA.
    Blood; 2014 Feb 20; 123(8):1152-8. PubMed ID: 24385535
    [Abstract] [Full Text] [Related]

  • 5. Developing a management plan for oral anticoagulant reversal.
    Dager WE.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S21-31. PubMed ID: 23640529
    [Abstract] [Full Text] [Related]

  • 6. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun 15; 22(139):155-9. PubMed ID: 23866358
    [Abstract] [Full Text] [Related]

  • 7. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM, Uhlmeyer EM, Schmidt DP, Schardt GL.
    Hosp Pract (1995); 2014 Dec 15; 42(5):108-25. PubMed ID: 25485923
    [Abstract] [Full Text] [Related]

  • 8. Bleeding and antidotes in new oral anticoagulants.
    Majeed A, Schulman S.
    Best Pract Res Clin Haematol; 2013 Jun 15; 26(2):191-202. PubMed ID: 23953907
    [Abstract] [Full Text] [Related]

  • 9. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis.
    Arch Cardiovasc Dis; 2013 Jun 15; 106(6-7):382-93. PubMed ID: 23810130
    [Abstract] [Full Text] [Related]

  • 10. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Lazo-Langner A, Lang ES, Douketis J.
    Crit Care; 2013 Jun 17; 17(3):230. PubMed ID: 23806169
    [Abstract] [Full Text] [Related]

  • 11. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ.
    Biomed Res Int; 2014 Jun 17; 2014():583794. PubMed ID: 25136597
    [Abstract] [Full Text] [Related]

  • 12. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH, Berger K, Lesch CA.
    J Crit Care; 2016 Dec 17; 36():166-172. PubMed ID: 27546767
    [Abstract] [Full Text] [Related]

  • 13. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R.
    Clin Res Cardiol; 2013 Jun 17; 102(6):399-412. PubMed ID: 23669868
    [Abstract] [Full Text] [Related]

  • 14. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A, Daw HA, Crowther MA.
    Cleve Clin J Med; 2013 Jul 17; 80(7):443-51. PubMed ID: 23821689
    [Abstract] [Full Text] [Related]

  • 15. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M.
    Circulation; 2011 Oct 04; 124(14):1573-9. PubMed ID: 21900088
    [Abstract] [Full Text] [Related]

  • 16. Managing new oral anticoagulants in the intensive care unit.
    Gass JA, Weeks PA.
    Crit Care Nurs Q; 2013 Oct 04; 36(4):390-9. PubMed ID: 24002428
    [Abstract] [Full Text] [Related]

  • 17. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 04; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 18. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, Berger RD, Calkins H, Marine JE.
    Ann Pharmacother; 2015 Mar 04; 49(3):278-84. PubMed ID: 25515868
    [Abstract] [Full Text] [Related]

  • 19. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M, Hjemdahl P, Holmström M, Ivert T.
    Lakartidningen; 2015 Mar 04; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract] [Full Text] [Related]

  • 20. An update of consensus guidelines for warfarin reversal.
    Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS, Australasian Society of Thrombosis and Haemostasis (ASTH).
    Med J Aust; 2013 Mar 04; 198(4):198-9. PubMed ID: 23451962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.